The experiences of fatigue in CFS, ME, PIFS

Research article abstract:

Background: Fatigue is a major problem among individuals with post-infectious fatigue syndrome (PIFS), also known as chronic fatigue syndrome or myalgic encephalomyelitis. It is a complex phenomenon that varies across illnesses. From a nursing perspective, knowledge and understanding of fatigue in this illness is limited. Nurses lack confidence in caring for these patients and devalue their professional role.

The aim of this study was to explore in-depth the experiences of fatigue among individuals with PIFS. A detailed description of the phenomenon of fatigue is presented. Increased knowledge would likely contribute to more confident nurses and improved nursing care.

Methods: A qualitative study with open interviews was employed.  In-depth interviews with patients were fully transcribed and underwent a qualitative content analysis. A maximum variation sample of 26 affected adults between 26–59 years old was recruited from a population diagnosed at a fatigue outpatient clinic.

Results: The fatigue was a post-exertional, multidimensional, fluctuating phenomenon with varying degrees of severity and several distinct characteristics and was accompanied by concomitant symptoms.  Fatigue was perceived to be an all-pervasive complex experience that substantially reduced the ability to function personally or professionally. A range of trigger mechanisms evoked or worsened the fatigue, but the affected were not always aware of what triggered it.

There was an excessive increase in fatigue in response to even minor activities. An increase in fatigue resulted in the exacerbation of other concomitant symptoms. The term fatigue does not capture the participants’ experiences, which are accompanied by a considerable symptom burden that contributes to the illness experience and the severe disability.

Conclusions: Although some aspects of the fatigue experience have been reported previously, more were added in our study, such as the dimension of awakening fatigue and the characteristic beyond time, when time passes unnoticed. We also identified trigger mechanisms such as emotional, neurological, social, financial, and pressure on oneself or from others.

This in-depth exploration of fatigue in PIFS provides an overview of the dimensions, characteristics, and trigger mechanisms of fatigue, thus making better clinical observations, early recognition, improved communication with patients and more appropriate nursing interventions possible

Fatigue in adults with post-infectious fatigue syndrome: a qualitative content analysis, by Eva Stormorken, Leonard A. Jason and Marit Kirkevold, in BMC Nursing 2015, 14:64, 28 November 2015

Posted in News | Tagged , , , , , | Comments Off on The experiences of fatigue in CFS, ME, PIFS

Dr Alan Light lecture on Youtube Thurs 3 Dec 2am

Free Education Meeting: “Partnerships to Accelerate Biomarker & Mechanism Discovery in ME/CFS and Fibromyalgia” Presented by Dr. Alan Light

Wednesday, December 2nd, 2015
8pm Central / Thursday 2am GMT
Salt Lake County Complex, North Building, 2001 S. State Street, SLC, UT

No registration required. Come as you are or tune in from anywhere!
LIVESTREAM http://www.youtube.com/c/OfferutahOrg/live

Posted in News | Tagged , , | Comments Off on Dr Alan Light lecture on Youtube Thurs 3 Dec 2am

Abnormal cytokine/chemokine profile in ME/CFS is associated with clinical symptoms

Research highlights:

  • Abnormal cytokine/chemokine profile in ME/CFS associated with clinical symptoms.
  • A cluster of IL-16, IL-7 and VEGF-A that may suggests neuro-inflammation as the pathogenesis mechanism in ME/CFS.
  • Potential diagnostic biomarkers proven by vigorous mathematical/statistical analysis.

Abstract:

Recently, differences in the levels of various chemokines and cytokines were reported in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as compared with controls.

Moreover, the analyte profile differed between chronic ME/CFS patients of long duration versus patients with disease of less than 3 years.

In the current study, we measured the plasma levels of 34 cytokines, chemokines and growth factors in 100 chronic ME/CFS patients of long duration and in 79 gender and age-matched controls.

We observed highly significant reductions in the concentration of circulating interleukin (IL)-16, IL-7, and Vascular Endothelial Growth Factor A (VEGF-A) in ME/CFS patients.

All three biomarkers were significantly correlated in a multivariate cluster analysis.

In addition, we identified significant reductions in the concentrations of fractalkine (CX3CL1) and monokine-induced-by-IFN-y (MIG; CXCL9) along with increases in the concentrations of eotaxin 2 (CCL24) in ME/CFS patients.

Our data recapitulates previous data from another USA ME/CFS cohort in which circulating levels of IL-7 were reduced.

Also, a reduced level of VEGF-A was reported previously in sera of patients with Gulf War Illness as well as in cerebral spinal fluid samples from a different cohort of USA ME/CFS patients.

To our knowledge, we are the first to test for levels of IL-16 in ME/CFS patients.

In combination with previous data, our work suggests that the clustered reduction of IL-7, IL-16 and VEGF-A may have physiological relevance to ME/CFS disease.

This profile is ME/CFS-specific since measurement of the same analytes present in chronic infectious and autoimmune liver diseases, where persistent fatigue is also a major symptom, failed to demonstrate the same changes.

Further studies of other ME/CFS and overlapping disease cohorts are warranted in future.

1. Introduction

Myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) is a complex and severely debilitating disease characterized by profound fatigue lasting for more than six months, post-exercise malaise, unrefreshing sleep, chronic pain, and cognitive dysfunction.

It is more common in middle-age women with an estimated prevalence of 0.8 million people in the USA and 0.4–1% in the world [1] and [2].

There is no laboratory test for diagnosis and no approved cure for the illness.

Diagnosis has been difficult, subjective and controversial leaving an urgent need for an objective laboratory-based diagnostic test for this very challenging illness.

Currently, the disease is diagnosed solely by subjective clinical symptoms [3] and evidence for an infectious etiology has been controversial [4], [5], [6], [7] and [8].

There is some evidence suggesting that the patients might suffer from a neuro-immune disorder [9] with neuroinflammation in the brain [10].

Alterations in the frequency and function of immune cells such as B cells and NK cells have been also reported [11] and [12].

Abnormalities in the concentrations of some circulating cytokines and chemokines have been previously reported [13], [14], [15], [16], [17] and [18] including three very recent studies of plasma and cerebrospinal fluid (CSF) samples from ME/CFS patients [19], [20]
and [21].

However, so far, there has been little confirmation of these abnormal analytes between different ME/CFS patient groups.

The objective of the current study was to measure the levels of various chemokines, cytokines and growth factors in the plasma of 100 ME/CFS patients from the USA along with 79 gender and age-matched controls to see if any consensus with previous studies
could be identified.

Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome, by Abdolamir Landia, David Broadhurst, Suzanne D. Vernon, D. Lorne J. Tyrrell, Michael Houghton, in Cytokine Vol 78, February 2016 pp27-36  [Available online 28 November 2015]

ME action: Study finds evidence of downregulated immune system in ME/CFS patients

Posted in News | Tagged , , , , , , | Comments Off on Abnormal cytokine/chemokine profile in ME/CFS is associated with clinical symptoms

Beyond tired: an overview of the IOM report on CFS/SEID

Article: Beyond Tired: Is chronic fatigue syndrome a real medical condition? Yes, according to a report from the Institute of Medicine, which urges physicians to treat it accordingly, by Dolan, Darrach in Neurology Now, October/November 2015, Vol 11, Issue 5, p 60–63

Gabriella Marinaccio, a 28-year-old teacher from Norwalk, CT, says she was forever on the go. “Rush, rush, rush. Undergraduate degree, then master’s, got married, started my doctorate, bought a house, bing, bam, boom!” She was a full-time teacher of English as a second language (ESL) while working on her doctorate, and still found time to socialize with her husband and their many friends. Then, in January 2014, her busy but idyllic life hit a large and unexpected speed bump.

“I woke up and thought I had the flu. I was achy and sick for about a week,” she recalls. When the severe diarrhea that accompanied the illness didn’t go away, her primary care doctor ordered a battery of tests, but couldn’t find anything wrong. She referred Marinaccio to a gastroenterologist, who ordered more blood work and did an endoscopy and colonoscopy, again without identifying an underlying cause. Finally, the gastroenterologist prescribed a course of antibiotics, and eventually her stomach settled down and the diarrhea stopped.

Then, in late September, Marinaccio tested positive for the flu, which was followed by a series of sinus, ear, and other minor viral infections—plus swollen lymph nodes in her neck, a sore throat, and achy muscles. By the end of October she was so unwell that it became impossible for her to continue teaching. By early November she had stopped working.

She saw several more doctors, including one specializing in infectious diseases and another in allergies and immunology. “They said there was nothing wrong with me. They did 50 pages of blood work and said everything was fine.”

A DIAGNOSIS AT LAST

But an appointment with Susan Levine, MD, an infectious disease and allergy and immunology specialist in New York City, finally provided some answers. Dr. Levine reviewed Marinaccio’s blood work and tests, examined her, and spent an hour listening to her. “Then she looked at me and said, ‘It’s chronic fatigue syndrome [CFS], and I think you also have active Epstein-Barr virus [the virus that causes mononucleosis].’” Dr. Levine drew blood to test for the virus and called one week later to confirm the diagnosis.

NO DIAGNOSTIC TESTS

A long, winding road to a CFS diagnosis is not unusual. There are no tests to identify and confirm biomarkers (indicators of a disease in the blood or body), and many doctors are unfamiliar with the clinical symptoms. A diagnosis is made based on symptoms, as well as a patient history and testing to rule out other conditions that may cause similar levels of fatigue, says Dr. Levine.

“Fatigue is a very common symptom with a wide variety of causes,” so ruling out other conditions is crucial, says Joseph R. Berger, MD, a professor of neurology at the Perelman School of Medicine of the University of Pennsylvania, an expert in neuro-immunology and neurovirology, and a Fellow of the American Academy of Neurology (FAAN). In a study published in the Multiple Sclerosis Journal in 2013, Dr. Berger reviewed the medical histories of thousands of people who were ultimately diagnosed with multiple sclerosis (MS) and found that one out of three was first diagnosed with CFS or general fatigue in the two to three years before they developed clinical MS. He believes that finding should serve as a warning to doctors against jumping to conclusions if they can’t find an immediate organic cause for a patient’s fatigue.

Many skeptics cite the fact that fatigue is a common symptom of many other conditions and the lack of clinical proof as evidence that CFS is primarily a psychological condition. “When I talk about chronic fatigue to other neurologists, up to half don’t believe it is a real medical entity,” says Thomas Sabin, MD, FAAN, vice chair of neurology at Tufts University School of Medicine.

Dr. Sabin understands the skepticism. For many years, he referred to himself as a “CFS agnostic,” but after decades of seeing patients and hearing similar stories of sudden symptoms, he is now convinced that the condition is real and devastating.

QUELLING THE CRITICS

To clarify the competing definitions and diagnostic criteria, the US Department of Health and Human Services and several other government agencies commissioned the non-profit Institute of Medicine (IOM) to evaluate the literature and recommend the best diagnostic criteria for doctors, based on the evidence.

The IOM panel, comprising 15 experts in clinical care, immunology, infectious diseases, pediatrics, neurology, and other relevant specialties, as well as people with CFS and their caregivers, held public hearings with advocates and researchers, opened an online portal for the public to add input, and considered more than 9,000 medical articles and studies on CFS written between 1950 and 2014.

As a result of its findings, the IOM panel proposed renaming the condition “systemic exertion intolerance disease,” or SEID, and defined it as a serious, chronic, complex, and systemic disease that frequently and dramatically limits the activities of those affected. In its final report, “Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness,” the panel concluded that CFS is, indeed, a “real” condition. (“Myalgic encephalomyelitis” means muscle pain or fatigue caused by inflammation in the brain and spinal cord.)
NEW PROPOSED DIAGNOSTIC CRITERIA

The panel identified five major symptoms: profound fatigue, exhaustion after exertion, unrefreshing sleep, cognitive impairment, and orthostatic intolerance (feeling lightheaded upon standing). For a diagnosis of CFS, patients must have the first three symptoms and at least one of the other two, according to the report.

1. Profound Fatigue

The first and most widely known symptom of CFS is debilitating fatigue. For a CFS diagnosis, this fatigue must come on suddenly, last for a minimum of six months, and go beyond a slight sleepiness or the temporary tiredness many feel after a busy week at work. “I call it ‘trimodal fatigue,’” says Dr. Sabin. “It’s the fatigue you feel when you miss a lot of sleep, combined with the mental fatigue after you play in a chess tournament and the physical fatigue after you exercise a lot. It’s all three types together.”

Marinaccio says her fatigue spills over into her social and family life, and she worries it may affect her relationships. She has often found herself physically unable to pick up the phone when a friend calls, and then cannot summon the mental energy to return the call. “Because I’m exhausted all the time, I have less patience. I don’t want to be that person who is moody and cranky all the time.”

Her fatigue is chronic but unpredictable in its intensity. Some days she can go to the supermarket to shop. Other days, she doesn’t even have the energy to make a sandwich.

2. Exhaustion After Exertion

People who have CFS describe the second core symptom, post-exertional malaise—a serious exacerbation of symptoms after mental, emotional, or physical exertion that may last anywhere from 24 hours to months—as a “crash” or “collapse.” “Their fatigue worsens with even minimal physical or mental exertion—sometimes only 10 minutes,” says Dr. Levine. “Other symptoms, such as cognitive abnormalities and sore throats and/or lymph node swelling, may flare up as well.”

Each person has a different fatigue threshold. For Marinaccio, a walk around the block is like running miles for an ordinary person; if she pushes herself beyond that point, she is affected for days.

“Post-exertional malaise is difficult to measure clinically because patients may be ‘normal’ in a resting state, and most doctors don’t have a treadmill or other equipment in their offices to test for it,” says Dr. Levine. Besides, “this symptom is variable, and [physicians] have to learn to ask the right questions.” She suggests doctors ask their patients how they feel the day after doing a strenuous activity.

Dr. Sabin says he regularly encourages his patients to do as much as they can but reminds them that overexertion may be counterproductive. Each person has to identify his or her own threshold and be active up to that point. Some evidence suggests that those who exert up to their threshold can improve, he says, and the threshold may even increase over time.

3. Unrefreshing Sleep

No matter how many hours they sleep, people with CFS universally report feeling unrested when they wake up. As with many symptoms of CFS, the intensity may vary. Initially, Marinaccio says she had difficulty staying asleep because her legs and arms felt achy. She would toss and turn, trying to stretch out. These days she sleeps soundly, but she feels no less tired or achy when she wakes up. As the day goes on, her symptoms lessen, and she feels most energetic in the evenings.

4. Cognitive Impairment

The IOM panel noted that many people who have CFS report that they can’t process information as quickly as they used to, and that they lack focus and are more forgetful. “The neurocognitive symptoms are slowed processing of new information, short-term memory problems, and diminished attentiveness, all of which worsen following exertion,” says Dr. Levine. This dulling of mental faculties can be as debilitating as the physical fatigue, but it is equally difficult to measure clinically, she says. And neurocognitive testing for the symptoms may not be covered by insurance.

Marinaccio, who used to love to read and discuss books, now can only concentrate long enough to listen to audio books in short bursts. Because of this, she has had to put her doctorate on hold for now.

5. Orthostatic Intolerance

The report also found that many people with CFS feel lightheaded or faint or have heart palpitations or other cardiac symptoms when they stand up or after standing for a long time. Once they sit or lie down, the symptoms diminish. This condition, called orthostatic intolerance, is normally diagnosed and treated by cardiologists—another example, Dr. Levine says, of how CFS cuts across medical specialties.

“It’s not clear whether orthostatic intolerance precedes CFS symptoms,” she says. “Patients may recall feeling lightheaded or having migraines or light sensitivity before they have symptoms of CFS, or these symptoms may be a consequence of the illness.”

A STEP IN THE RIGHT DIRECTION

Dr. Sabin says the IOM’s proposed diagnostic criteria is “a simplification [of the condition], perhaps,” but one that clarifies the core symptoms and makes it easier to diagnose. He also thinks the report will draw attention to CFS, and he is happy that it confirms that the syndrome causes real suffering and should not be dismissed by doctors.

As the chair of the US Federal Advisory Committee on CFS, which is responsible for evaluating and implementing the IOM report, Dr. Levine says there is still debate about whether other common symptoms of CFS, such as viral infections, muscle and joint pain, and swollen lymph glands, should be included as part of the diagnostic criteria. Otherwise, she thinks the panel’s proposed criteria are a good start.

Dr. Berger adds that he believes too many people whose only symptom is fatigue are diagnosed with CFS. He thinks that physicians should apply the new diagnostic criteria for CFS strictly, and if their patients don’t satisfy them in full, they should look elsewhere for underlying causes.

SEARCHING FOR A CAUSE

Since chronic fatigue was first reported in the 1930s, researchers have put forward theories about its cause, but no single virus or environmental trigger has been proven and no single mechanism has been found. A 1934 outbreak in a hospital in Los Angeles was thought to be a mutation of the poliovirus. An outbreak in 1955 in London’s Royal Free hospital, which affected many staff members, was considered highly contagious. Another episode in the 1980s near Lake Tahoe was thought to be a chronic form of the Epstein-Barr virus.

Recently, many viruses and infectious agents have been studied as potential causes or triggers for the condition, including the human herpesvirus 6, Candida albicans (a fungus that causes yeast infections), and bornaviruses (a family of viruses found in farm animals and birds that affect neurons). However, none has been shown to be the single or most likely cause of CFS. “So far, we have not been able to identify an infectious agent,” says Dr. Berger, who doesn’t believe a single agent is likely to be behind all cases of CFS and is not convinced that a chronic or lingering infection gives rise to the symptoms. “It’s certainly conceivable that in a subpopulation [of people with CFS] there has been some change in their immune function triggered by an infection and that proinflammatory cytokines [proteins that regulate the body’s response to infection and inflammation, which in this case make disease worse] are now affecting their brains and giving rise to their symptoms,” he adds.

The lack of a proven cause or mechanism adds to the amorphous quality of the condition. After an exhaustive analysis of the medical literature, the IOM committee could not come to any conclusions about what causes CFS, how it works within the body, or how to treat it. The literature offered no consensus on the process or natural progression of the syndrome.

A DYNAMIC CONDITION

Chronic fatigue syndrome morphs over time, says Dr. Levine. “Within the first year of someone getting ill, there are many abnormalities in the blood and inflammatory markers, but these fade as time goes on.” This may be one reason it has been so difficult to find a single biomarker.

However, Dr. Levine thinks researchers are getting closer to finding these biomarkers. Jose Montoya, MD, and his colleagues at the Stanford ME/CFS Initiative, for example, have found evidence of inflammation and structural abnormalities in the brains of people with CFS. But, Dr. Levine cautions, “it’s so complex, we’re only scratching the outer surface. It’s going to take a while.”

Dr. Sabin agrees. “Something triggers an immune response,” he says, but the research can’t yet describe or explain it.

TREATING SYMPTOMS

Because there is no recognized treatment for CFS, doctors can only treat individual symptoms like pain, difficulty sleeping, and opportunistic infections. Marinaccio still takes medications for acid reflux and irritable bowel syndrome, but her doctor is slowly weaning her off them. She also takes an antiviral drug prescribed by Dr. Levine for the active Epstein-Barr virus and to reduce any other potential viral load, as well as an antihistamine prescribed by her primary care doctor for her allergies, which worsened with her CFS. She has also changed her diet, avoiding processed foods, cutting back on meat, and eating more greens and berries.

Dr. Sabin shares strategies with his patients with CFS for adapting to the illness and maintaining productivity. “I tell my patients to consider and examine how they spend their time and try to think of ways to use what energy they have productively,” he says. To help them do that, he often recommends cognitive behavioral therapy, a form of therapy that teaches people how to counter negative or inaccurate thoughts and cope with challenging or stressful situations. It’s important to avoid making the disease a lifestyle, he says.

A MIXED PROGNOSIS

Some people with CFS are profoundly disabled, while others recover, says Dr. Sabin. In general, though, symptoms can persist for years, and most people never regain their original level of health or functioning.

Marinaccio cried when she was diagnosed with CFS, but Dr. Levine reassured her that because it was caught so early, she has a better chance of improving than most. “I think it’s fair to say that most patients improve about 30 to 50 percent. They do better if they are treated, stop working, or both within 18 months of becoming ill. The outcomes are so variable, and no one has done long-term studies [on the condition].”

Marinaccio says she feels slightly better since she was first diagnosed last Thanksgiving. “I’m managing my fatigue and learning how to pace myself.” Even small changes help: Instead of writing Christmas cards by hand, for example, she now sends e-cards. Instead of shopping at a store for every essential, she orders items like paper towels and cleaning products online in bulk. This allows her to use the energy she has for more important things like maintaining relationships and teaching her class.

She also believes she has learned a lesson from her diagnosis. “I was always go, go, go. Now I realize life is not all about doing and achieving. I have started to appreciate what I have.” She has started a blog to chronicle her condition and how she is dealing with it, in hopes of helping others in similar situations. And she wants people to seek treatment as early as they can—before they “dig themselves into a hole they can’t get out of.”

WEB EXTRA: For more information on myalgic encephalomyelitis/chronic fatigue syndrome, including a proposed name change, visit http://bit.ly/NN-chronicfatigue.

Resources for CFS

* The complete IOM report can be downloaded for free or purchased in hard copy: http://bit.ly/IOM-CFS-report

* The Chronic Fatigue Initiative at the Hutchins Family Foundation is committed to supporting and publicizing research into causes and possible treatments: http://cfinitiative.org

* The Stanford Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Initiative is investigating the possibility that CFS may be caused or triggered by an infectious agent or the body’s immune response to an infection: http://bit.ly/Stanford-CFS

* The US Centers for Disease Control and Prevention offers a resource page: http://cdc.gov/cfs

* Phoenix Rising offers support, forums, and further resources: http://phoenixrising.me

* The Solve ME/CFS Initiative is dedicated to finding a cure for the syndrome through patient-centered research: http://solvecfs.org

* The End ME/CFS Project, part of the Open Medicine Foundation, supports the ME/CFS Severely Ill, Big Data Study, which hopes to find a clinically useful diagnostic biomarker: http://bit.ly/End-MECFS

 

 

Posted in News | Tagged , , , , , , , , | Comments Off on Beyond tired: an overview of the IOM report on CFS/SEID

Dry eye disease in patients with chronic pain

Research abstract:

PURPOSE: To investigate clinical characteristics of dry eye disease (DED) patients with a chronic pain syndrome.

DESIGN: Cross-sectional study

METHODS: 425 patients of a tertiary care DED patient cohort in the Netherlands were included. Chronic pain syndromes, irritable bowel syndrome, chronic pelvic pain and fibromyalgia were assessed by questionnaires. Outcome variables were the Ocular Surface Disease Index (OSDI) symptom questionnaire, tear osmolarity, Schirmer test, tear breakup time, conjunctival hyperaemia, staining of the cornea and conjunctiva, and amount of mucus. Outcomes were cross-sectionally compared between DED patients with a chronic pain syndrome versus those without.

RESULTS: A total of 74 (17%) out of 425 DED patients had at least one chronic pain syndrome. The total symptom score was significantly higher in DED patients with a chronic pain syndrome than in those without (45.8 vs 33.8, P<.0005). Moreover, patients with a chronic pain syndrome scored higher on every single subscale of the 12-item OSDI symptom questionnaire. However, ocular signs were similar or even less severe in these patients. Similarly, in 64 DED patients from the population-based cohort TwinsUK, patients with a chronic pain syndrome (n=24, 38%) had higher subscale and total (34.1 vs 14.4, P=.001) symptom scores.

CONCLUSION: In DED patients, chronic pain syndromes are common and associated with increased severity of DED symptoms across all domains of the OSDI, even though objective ocular surface signs are no worse. In clinical practice, more awareness of chronic pain syndromes might help in understanding the discrepancy between signs and symptoms in DED.

Clinical characteristics of dry eye patients with chronic pain syndromes by Vehof J, et al. in Am J Ophthalmol, 2015 Nov 18  pii: S0002-9394(15)00705-9 [Epub ahead of print]

Posted in News | Tagged , , , , , | Comments Off on Dry eye disease in patients with chronic pain

The brain’s frontal cortex works inefficiently in children with CFS

Research abstract:

The ability to divide one’s attention deteriorates in patients with childhood chronic fatigue syndrome (CCFS). We conducted a study using a dual verbal task to assess allocation of attentional resources to two simultaneous activities (picking out vowels and reading for story comprehension) and functional magnetic resonance imaging.

Patients exhibited a much larger area of activation, recruiting additional frontal areas. The right middle frontal gyrus (MFG), which is included in the dorsolateral prefrontal cortex, of CCFS patients was specifically activated in both the single and dual tasks; this activation level was positively correlated with motivation scores for the tasks and accuracy of story comprehension.

In addition, in patients, the dorsal anterior cingulate gyrus (dACC) and left MFG were activated only in the dual task, and activation levels of the dACC and left MFG were positively associated with the motivation and fatigue scores, respectively.

Patients with CCFS exhibited a wider area of activated frontal regions related to attentional resources in order to increase their poorer task performance with massive mental effort. This is likely to be less efficient and costly in terms of energy requirements. It seems to be related to the pathophysiology of patients with CCFS and to cause a vicious cycle of further increases in fatigue.

Less efficient and costly processes of frontal cortex in childhood chronic fatigue syndrome, by Mizuno K, Tanaka M, Tanabe HC, Joudoi T, Kawatani J, Shigihara Y, Tomoda A, Miike T, Imai-Matsumura K, Sadato N, Watanabe Y. in Neuroimage Clin. 2015 Sep 10;9:355-68

 

 

 

 

Posted in News | Tagged , , , , , , | Comments Off on The brain’s frontal cortex works inefficiently in children with CFS

The chokehold behavioural treatments have on ME/CFS

American health blogger Cort Johnson looks at which ME/CFS treatment studies have been published since the start of 2013.

He highlights that there has been a lack of drug studies and that most of the these studies were small.

Extracts:

“With only one type of non-behavioral treatment, acupuncture, being assessed in more than one study, few of these treatment options have a chance of going mainstream. (CBT/GET studies showed up in 38 citations). The countries that dominated the behavioral studies (n=36) – the UK and the Netherlands  – showed a distinct preference for the types of studies they wish to fund; they produced only three non-behavioral studies.”

“The implications of two governments [UK & Dutch] focusing substantial funding on one treatment type is clear: a dramatic restriction of the possible treatment options recommended for doctors and ultimately for most patients. Few of the treatments ME/CFS experts use showed up in this survey and few of which are available to patients seeing non-experts.

When a slim portion of the possible treatment options for a disease gets outsized attention three things happen: that treatment gets an undue focus in the media, doctors and patients treatment options are limited, and patients miss possibilities for treatment.”

One [factor] is the unwillingness of federal funders such as the NIH to fund research that will reveal viable treatment targets for drug manufacturers. This poor research funding has left ME/CFS a biological mystery. This has opened the door, as has happened so many times to so many diseases over time, to a behavioral interpretation of it.

The willingness of federal funders in the UK and Europe to pump large amounts of money into the behavioral treatment trials has effectively exploited that opening. A significant portion of the medical profession either accepts a behavioral interpretation of ME/CFS or has little or no knowledge of other possible treatments.

Treatment Survey

Behavioral = 53 citations

  • CBT alone or CBT/GET -38 citations
  • Graduated exercise therapy – 6
  • Pacing — 3
  • Yoga — 2
  • Others –  8 • Multidisciplinary Study • Relaxation Therapy • Stress Management • Meditation – symptom management • Self-management • Guided Self Instruction • Symptom control • Emotional involvement significant others

Non-Behavioral = 25 citations

Drugs:

  • Rituximab (29 people) –  Norway
  • Cytokine blocker (50 people) – Netherlands
  • Clonidine (176) – Norway
  • IVIG (1) – Italy
  • Ondansetron (5)- Netherlands
  • Valganciclovir (30) – US
  • lisdexamfetamine dimesylate (26) – US

Supplements and Diet:

  • GcMAF – Japan – case studies – 3 people
  • B-12/Folic Acid – Sweden
  • Diet – Review article – US
  • COQ10 – Spain
  • Herbal China  review – China
  • Vit D – UK
  • Herb – Italy – II – french oak wood extract
  • CoQ10 – Spain
  • Traditional Chinese Medicine – Review – China
  • Multivitamin – Serbia
  • Acetaminophen – Belgium

Other and Alternative Health:

  • Acupuncture –  S Korea, China, S Korea
  • Hyperbaric Oxygen Therapy – Turkey
  • Mercury removal – 1 person case study – Korea
  • Other
    Multidisciplinary Treatments – Italy

Countries of Origin:

US – 4 Italy – 3 Korea – 3 China – 3 Norway — 3 Netherlands – 2 Spain – 2 Belgium – 1 Turkey – 1 Serbia – 1 Sweden – 1 UK- 1

Read more: The Chokehold Behavioral Treatments Have on Chronic Fatigue Syndrome,  by Cort Johnson, Nov 11, 2015

Posted in News | Tagged , , , , , | Comments Off on The chokehold behavioural treatments have on ME/CFS

To future GPs – psychosomatic should not be the default suspicion re ME/CFS

Time to swot up on chronic fatigue – Future general practitioners need to be made aware that “psychosomatic” should not be the default suspicion, by Michael Brooks in the New Statesman, Nov 12 2015

Around 250,000 people in the UK suffer from chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME). The symptoms include debilitating tiredness, pains, dizziness, insomnia and depression. The standard recommended treatment has three strands: cognitive behavioural therapy, an exercise programme (“graded exercise therapy”) and medication that counters some of the pain, nausea, sleeping problems and other symptoms.

That prescription has been reinforced by a review published in the journal Lancet Psychiatry, which followed a group of sufferers and concluded that cognitive behavioural therapy and graded exercise therapy are better than “specialised medical care”.

The ME Association, however, responded with a detailed criticism of the study. It complains that cognitive behavioural therapy treatment attaches a label that marks CFS as a psychological disease while doing little good. Moreover, graded exercise therapy makes a significant proportion of people worse, it argued, and the hypothesis that those with CFS respond to the therapy because they are inactive and deconditioned “is no longer tenable”. The association pointed to research showing that sufferers have “significant abnormalities in the muscle, brain and immune system”, which are likely to contribute to CFS symptoms and induce fatigue in those compelled, against their inclination, to exercise as part of their treatment.

There is something to these objections. In 2011, researchers in Norway announced an accidental discovery: an anti-cancer drug called Rituximab had eased a cancer patient’s CFS symptoms.

A larger follow-up study published in July this year found that the initial discovery had been no fluke. Of the 29 people in the trial, 18 experienced significant relief from CFS symptoms, with  11 of them still feeling good after three years and some still in remission, with no symptoms, after five. Now, 150 people are taking part in a new study on the effects of Rituximab on CFS. The drug destroys the immune system’s white blood cells; these cells may have been playing a role in creating CFS symptoms.

Things may be about to improve for sufferers. The US National Institutes of Health announced that it has been spending too little on the disease and is planning a study on the possible role of infection in triggering CFS. Oversight of CFS studies has been moved from the Office of Research on Women’s Health to the National Institute of Neurological Disorders and Stroke. In other words, it is being taken seriously.

Educating future doctors about CFS would also help. According to a study into medical students’ attitudes to the syndrome, published by researchers at the University of Manchester, UK students acquire their knowledge “largely from informal sources” and they “expressed difficulty understanding chronic fatigue syndrome within a traditional biomedical framework”. Many didn’t see how it was a medical problem – and some considered sufferers as malingerers or time-wasters.

Future general practitioners need to be made aware that “psychosomatic” should not be the default suspicion. A compromised immune system now looks like a reasonable diagnosis. Although treatments are not yet ready, at least sufferers will not be cajoled on to therapies that might prove problematic. Remember: “First, do no harm.”

NB Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is At the Edge of Uncertainty: 11 Discoveries Taking Science by Surprise. 

Posted in News | Tagged , , , , , , , , , , | Comments Off on To future GPs – psychosomatic should not be the default suspicion re ME/CFS

Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab

Blog articleOffers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate]

A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay up to 200,000 kroner.

In 2011 cancer doctors Øystein Fluge and Olav Mella  published the first results of a randomized study that demonstrated the efficacy of the cancer drug rituximab in patients with chronic fatigue syndrome CFS/ME.

20 to 30 patients
Research is still on this at Haukeland, and medicine’s effect on chronic fatigue syndrome is not clear. But oncologist and professor of medicine, Dagfinn Øgreid at Kolibri Medical AS in Sandnes, give this treatment in Sandnes.

By private clinic has between 20 and 30 patients received treatment, and paid up to 200,000 kroner, according Øgreid.

We have treated with rituximab in a few months. We believe the data published are good, and so impressive that it is hard not to give this treatment in a proper frame. I guess we have helped someone who instead of going to the USA and pay millions, have received similar treatment with us, says Øgreid Dagens Medicine.

Øgreid says he follows approach to research in progress at Haukeland.

We relate to protocol at Haukeland. The study is very clearly defined, and we can detect both effect and side effect as usual, he said.

Did not know anything about this
Cancer Physician and researcher at Haukeland, Øystein Fluge, one of the researchers behind the treatment method, says to Dagens Medicine that he only recently heard about the services provided by Kolibiri Medical.

Øgreid has not been in contact with us and we did not know anything about this offer until about a month ago. We believe that patients should not receive this treatment outside clinical trials, says Fluge Dagens Medicine.

As it says in our last article then this is no established medical truth. It’s too early. A randomized study will clarify further whether this has anything to offer, says Fluge.

Øgreid specifies that there are strict criteria for getting treatment at him:

We are strict on criteria. Patients must have a diagnosis of ME, and have paper from a public reputable hospital or specialist at all to be concerned.

Patients pay about 200,000 for treatment. What do you think about the price?

There is a high price, but overall is 85 percent of the cost of drug cost. We charge for monitoring and medical consultation. I think the public ought to offer this treatment, says Øgreid.

According Øgreid is two to three patients become completely healthy so far. Fluge and Mella works based on the following hypothesis:

ME / CFS in a sub-group of patients could be a variant of an autoimmune disease. The pattern of response and relapse after rituximab-intervention matches the response courses at other recognized autoimmune diseases. ME / CFS is often triggered by infections, it is clear predominance of women, and there seems to be a genetic predisposition.

Can ME / CFS responsive to immunomodulatory treatment?

Posted in News | Tagged , , , , , , | 1 Comment

250 donations to ‘Solve ME/CFS’ needed by 1 Dec 2015

Giving Tuesday:

 

Help Solve ME/CFS initiative to meet their challenge and receive $50,000 by making a Giving Tuesday donation. An anonymous donor has put up a $50,000 challenge donation that they will receive, if they get 250 gifts of any amount by Tuesday 1 December 2015.

Any donor who makes a gift of $100 or more will receive a custom-made Solve ME/CFS Initiative bracelets, handcrafted by artisans in Costa Rica for Pura Vida Bracelets. Bracelets are adjustable in size and unisex in design.

Solve ME/CFS initiative’s mission is to make ME/CFS widely understood, diagnosable, and treatable. They will do this by stimulating participatory, patient centered research aimed at the early detection, objective diagnosis and effective treatment of ME/CFS through expanded public, private and commercial investment.

Posted in News | Tagged , , , | Comments Off on 250 donations to ‘Solve ME/CFS’ needed by 1 Dec 2015